Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 16080074.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine occurred in 23% of patients. Development of antibody to hepatitis e antigen did not prevent hepatic flare. One patient with marked bridging fibrosis required liver transplantation. Patients with advanced liver disease are at risk for hepatic flare with decompensation if active treatment is withdrawn (e.g., when highly active antiretroviral treatment is modified).
Medical subject headings
- Antiviral Agents
- Deoxycytidine
- Hepatitis B, Chronic